TY - JOUR T1 - Estimating the incidence of typhoidal <em>Salmonella</em> from cross-sectional serology using antibody dynamics following infection JF - medRxiv DO - 10.1101/2021.10.20.21265277 SP - 2021.10.20.21265277 AU - Kristen Aiemjoy AU - Jessica C. Seidman AU - Senjuti Saha AU - Sira Jam Munira AU - Mohammad Saiful Islam Sajib AU - Syed Muktadir Al Sium AU - Anik Sarkar AU - Nusrat Alam AU - Farha Nusrat Jahan AU - Md. Shakiul Kabir AU - Dipesh Tamrakar AU - Krista Vaidya AU - Rajeev Shrestha AU - Jivan Shakya AU - Nishan Katuwal AU - Sony Shrestha AU - Mohammad Tahir Yousafzai AU - Junaid Iqbal AU - Irum Fatima Dehraj AU - Yasmin Ladak AU - Noshi Maria AU - Mehreen Adnan AU - Sadaf Pervaiz AU - Alice S. Carter AU - Ashley T. Longley AU - Clare Fraser AU - Edward T. Ryan AU - Ariana Nodoushani AU - Alessio Fasano AU - Maureen Leonard AU - Victoria Kenyon AU - Isaac I. Bogoch AU - Hyon Jin Jeon AU - Andrea Haselbeck AU - Se Eun Park AU - Raphael Zellweger AU - Florian Marks AU - Ellis Owusu-Dabo AU - Yaw Adu-Sarkodie AU - Michael Owusu AU - Peter Teunis AU - Denise O. Garrett AU - Stephen P. Luby AU - Farah Naz Qamar AU - Samir K. Saha AU - Richelle C. Charles AU - Jason R. Andrews Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/21/2021.10.20.21265277.abstract N2 - The incidence of enteric fever, an invasive bacterial infection caused by typhoidal Salmonellae, is largely unknown in regions lacking blood culture surveillance. New serologic markers have proven accurate in diagnosing enteric fever, but whether they could be used to reliably estimate population-level incidence is unknown. We collected longitudinal blood samples from blood culture-confirmed enteric fever cases enrolled from surveillance studies in Bangladesh, Nepal, Pakistan and Ghana and conducted cross-sectional sero-surveys in the catchment areas of each surveillance site. We used ELISAs to measure quantitative IgA and IgG antibody responses to Hemolysin E (HlyE) and S. Typhi lipopolysaccharide (LPS). We used Bayesian hierarchical models to fit two-phase power-function decay models to the longitudinal sero-responses among enteric fever cases and used the joint distributions of the peak antibody titers and decay rate to estimate population-level incidence rates from cross-sectional serosurveys. The longitudinal antibody kinetics for all antigen-isotypes were similar across countries and did not vary by clinical severity. The incidence of typhoidal Salmonella infection ranged between 41.2 per 100 person years (95% CI: 34.0-50.1) in Dhaka, Bangladesh to 5.8 (95% CI: 4.8-7.1) in Kavrepalanchok, Nepal and followed the same rank order as clinical incidence estimates. The approach described here has the potential to expand the geographic scope of typhoidal Salmonella surveillance and generate incidence estimates that are comparable across geographic regions and time.One sentence summary We describe an approach to estimating typhoidal Salmonella infection incidence from cross-sectional serologic data, using longitudinal antibody responses to HlyE and LPS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by th eBill and Melinda Gates Foundation (grant INV-000572)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Boards (IRBs) in the United States (Centers for Disease Control and Prevention; Stanford University Institutional Review Board), Bangladesh (Bangladesh Institute of Child Health Ethical Review Committee), Nepal (Nepal Health Research Council Ethical Review Board), Pakistan (AKU Ethic Review Committee and Pakistan National Bioethics Committee), Korea (International Vaccine Institute IRB, No. 2015-006), Belgium (Institute of Tropical Medicine Antwerp Institutional Review Board, Belgium; Universiteit Antwerpen, Comite voor medische Ethiek, Belgium), and Ghana (Kwame Nkrumah University of Science and Technology, School of Medical Sciences; and Komfo Anokye Teaching Hospital, Committee on Human Research, Publication and Ethics, Ghana) approved the study forms and protocols. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -